FDA label
What is Vumerity used for?
Vumerity contains diroximel. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Vumerity?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Vumerity, capsule
Indications and Usage, quoted from the label by Biogen Inc. (NDA211855). Cross-references to other label sections are left out.
VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Source: DailyMed label, set id 2d74414f-6b83-4ea2-9a95-3cecabbce774, version 16, effective May 29, 2025. NDC 64406-020, one of 1 listing for this product.
Questions
What is Vumerity used for?
The FDA label says: “VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.